CEO Olivier Loeillot highlighted strong Q1 organic revenue growth, reporting an 11% organic increase, with non-COVID growth reaching 14%. Proteins showed the strongest performance, surpassing ...
According to Adhishthana principles, a stock typically breaks out of its Cakra pattern in Phase 9, which starts a strong upward move. This marks the beginning of the Himalayan Formation, a rally that ...
As of Tuesday, February 24, Repligen Corporation’s RGEN share price has dipped by 6.43%, which has investors questioning if ...
Investing.com - KeyBanc hat die Einstufung für Repligen (NASDAQ:RGEN) mit "Overweight" und einem Kursziel von 220,00 $ bestätigt.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results